# Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

> **NCT01231802** · PHASE2 · UNKNOWN · sponsor: **Adherex Technologies, Inc.** · enrollment: 140 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Eniluracil
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01231802
- **Lead sponsor:** Adherex Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-04
- **Primary completion:** 2012-08
- **Final completion:** 2013-01
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2012-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231802, "Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01231802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*